Use of semaglutide for aesthetic and weight loss purposes by non-diabetic individuals
DOI:
https://doi.org/10.33448/rsd-v12i12.43905Keywords:
Semaglutide; Weight loss; Glucagon-like peptide 1.Abstract
Objective: To analyze the impact and factors that contribute to the use of semaglutide for purposes weight loss by non-diabetic individuals. Methods: The present study is an integrative literature review, through searches in PubMed, SciELO and VHL databases. Results: By performing the bibliographic search in the databases, different findings related to the slimming effects of semaglutide were evidenced, in a dose-dependent manner and according to the duration of treatment. In addition, it has been shown to be not only superior in reducing body weight compared to other antidiabetic drugs, but also cardioprotective, despite the commonly reported occurrence of gastrointestinal side effects such as nausea and vomiting. Final considerations: In this way, semaglutide appears as a therapeutic option that demonstrates a perspective of effectiveness and tolerability with higher rates than other drugs previously used for the treatment of obesity and chronic overweight.
References
Anam, M., Maharjan, S., Amjad, Z., Abaza, A., Vasavada, A. M., Sadhu, A., Valencia, C., Fatima, H. & Nwankwo, I (2022). Efficacy of semaglutide in treating obesity: a systematic review of randomized controlled trials (RCTs). Cureus, 14(12), 1-9.
Andrade, J. V. M., Arruda, E. A. Rocha, L. O. & Carneiro, V. M. P. (2022). Uso de semaglutida como coadjuvante no controle da obesidade. Revista Conhecendo Online: humanas e sociais, 181-197.
Apovian, C. M. (2022). Obesity: definition, comorbidities, causes, and burden. Am J Manag Care, 22(7), 178-85.
Camilleri, M., Acosta, A. (2018) Combination Therapies for Obesity. Metab Syndr Relat Disord, 16(8), 390-394.
Carrara, C. (2022). Semaglutide is effective for the treatment of obesity and overweight. Evid actual práct ambul, 25(3), 1-3.
Castro, B. R., Reis, L. S. & Paixão, J. A. (2022). Segurança e eficácia da semaglutida, liraglutida e sibutramina no auxílio do tratamento da obesidade. Revista Ibero-Americana de Humanidades, Ciência e Educação, 8 (5), 2925-2941.
Chao,A. M. Tronieri, J. S., Amaro, A. & Wadden, T. A. (2022). Clinical insight on Semaglutide for chronic weight management in adults: patient selection and special considerations. Drug Design, Development and Therapy, 16, 4449-4461
Christou, G. A., Katsiki, N., Blundell, J., Fruhbeck, G. & Kiortsis, D. N. (2019). Semaglutide as a promising antiobesity drug. Obesity Reviews, 20(6), 805-815.
Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A. & Skovgaard, D. (2021). The effect of semaglutide 2.4mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab, 23(3), 754-762.
Gao, X., Hua, X., Wang, X., Xu, W., Yu, Z., Shi, C. & Gu, M. (2022). Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol, 13, 1-14.
Ghusn, W., Rosa, A.D., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., Hurtado, M.D. & Acosta, A. (2022). Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw Open 5(9), 1-3.
Gomes, H. K. B. C. & Trevisan, M. (2021). O uso do ozempic (semaglutida) como medicamento off label no tratamento da obesidade e como auxiliar na perda de peso. Rev. Artigos. Com, 29, 1-7.
Kane, M. P., Triplitt, C. L. & Solis-Herrera, C. D. (2021). Management of type 2 diabetes with oral semaglutida: pratical guidance for pharmacists. Am J Health Syst Pharm, 78 (7), 556-567.
Kennedy, C., Hayes, P., Salama, S. & Hennessy, M, Fogacci, F (2023). The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis. J Clin Med, 12(3), 772.
Knudse, L. B. & Lau, J. (2019). The discovery and development of liraglutide and semaglutide. Front Endocrinol, 10(155), 1-32
La Parte, M. C., Pérez, A. F. & Ferran, M. R. (2022). Una visión actual del tratamiento farmacológico para la obesidad. Rev Esp Nutr Comunitaria, 28(4), 1-20.
Liu Q., Cai B.Y., Zhu, L.X., Xin, X., Wang, X, An, Z.M., Li, S., Hu, Y.Y. & Feng, Q. (2020). Liraglutide modula microbioma intestinal e atenua fígado gorduroso não alcoólica em camundongos. Life Sci, 15 (261), 118457.
Meldrum, D. R., Morris, M. A. & Gambone, J. C. (2017). Obesity pandemic: causes, consequences, and solutions-but do we have the will?. Fertil Steril, 107(4), 833-839.
Montalván, D. E. A., Fuenmayor, C. F. P. & Benavides, R. E. O. (2022). Relación entre el fármaco semaglutida y la reducción de peso en pacientes com obesidad: una revisión sistemática. Vive Rev. Salud, 5(15), 698-714.
Popoviciu, M. S. Pãduraru, L., Yahya, G. & Metwally, K. (2023). Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. Jornal Internacional de Ciências Moleculares-Multidisciplinar Digital Publishing Institute (MDPI), 24(13), 10449.
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sorrig R., Wadden, T. A., Wizert A. & Garvey W. T. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the step 8 randomized clinical trial. JAMA, 327(2), 138-150.
Silva, L. E. S, Oliveira, M. M, Stopa, S. R, Gouvea, E. C. D., Ferreira, K. R. D., Santos R. O., Valença Neto, P. F., Macário, E. D. & Sardinha, L. M. V. (2021). Tendência temporal da prevalência do excesso de peso e obesidade na população adulta brasileira, segundo características sociodemográficas, 2006-2019. Epidemiol. Serv. Saude, 2021, 30(1), 1-13.
Silva, R. M. & Bezerra, I. C. Estudos quantitativos: enfoques teóricos e técnicas de coleta de informações. Sobral: Edições UVA, 2018.
Singhm G., Krauthamer, M. & Bjalme-evans, M. (2022). Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med, 70(1), 5-13.
Sokoloski, B. V. F., Nery, G. K. S., Campestrini, M. D. P. & Soares, V. E. H. (2023). Farmacoterapia do emagrecimento: efeito rebote do uso off label da semaglutida. Trabalho de conclusão de curso – Universidade Sociedade Educacional de Santa Catarina, Jaraguá do Sul.
Souza, M. T., Silva, M. D. & Carvalho, R (2010). Revisão Integrativa: o que é e como fazer. Einstein, 8 (1), 102-6.
Tan, H. C., Dampil, O. A. & Marquez, M. M. (2022). Efficacy and safety oof semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis. J ASEAN Fed Endocr Soc, 37(2), 65-72.
Timo, A. M. T., Meneghetti, A. J. P., Barbosa, G. P., Barros, M. M., Souza, V. R., Andrade, I. S., Tres, A. B., Souza, M. M. & Soyer, A. B. (2022). Uso de semaglutina no tratamento da obesidade. Brazilian Journal of Health Review, 5(3).
Weghuber D., Barret, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea L. D., Sorrig, R. & Arslanian S. (2022). Once-weekly semaglutide in adolescents with obesity. N Engl J Med., 2022, 387(24), 2245-2257.
Wilding, J. P. H., Batterhan, R. L., Davies, M., Gaal, L. F. V., Kandler, K., Konakli, K., Lingvay, I., McGowan, B., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K. & Kushner, R. F. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: the step 1 trial extension. Diabetes Obes Metab, 24(8), 1553-1564.
Zanatta, M. C. A., Rocha, F. S., Fumagali, T. A. S., Backes, G. A., Sambini, T. B., Matsukuma, I. S., Martinez, G. A., Benedetti, A. T. S. & Pereira, L. A. A. (2023). A semaglutida aplicada ao tratamento da obesidade: perspectivas clínicas na literatura. Research, Society and development, 12 (9), 1-11.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Sávio Pessoa Pires; Bárbara Alves Leal; Isabela Paiva Souza; Klaiy Christina Ferraz Rangel; Luciano Evangelista dos Santos Filho
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
